Nancy Lurker
Nancy Lurker's purchase track record
Nancy Lurker has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/16/2024 | EYPT | $25K | +15.6% | -18.0% | +10.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
COLL Outlook Supported by ADHD Trends, Low Generic Risk, Oppenheimer. Oppenheimer notes that Collegium Pharmaceutical's outlook is bolstered by strong demand for ADHD treatments and a low risk of generic competition. The firm’s focus on these areas may help sustain revenue growth. The stock is currently trading near its 52‑week low of $21.43, close to a support level that has been tested repeatedly.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Yahoo article highlights EYPT as a potential portfolio addition. A recent Yahoo article discussed EyePoint Inc. (EYPT) and listed reasons why the stock could be considered for a portfolio. The piece referenced the company's analyst consensus target of $25.91 and its 52‑week range of $2.93 to $19.11. The article’s positive tone adds to current market conversation around the stock.
Transaction History
| ALKS | ▲ Buy | Option Exercise | 6,142 | — | 5/21/2026 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,475 | $55K | 5/21/2026 | View on chart |
| COLL | ▲ Buy | Grant | 8,741 | $0 | 5/14/2026 | View on chart |
| COLL | ▼ Sell | Open Market | 4,500 | $162K | 5/13/2026 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 3,751 | — | 4/11/2026 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 901 | $30K | 4/11/2026 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 75,133 | $0 | 1/6/2026 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 12,666 | $0 | 1/5/2026 | View on chart |
| EYPT | ▼ Sell | Open Market | 9,300 | $140K | 12/4/2025 | View on chart |
| EYPT | ▼ Sell | Open Market | 500 | $7K | 11/28/2025 | View on chart |
| EYPT | ▼ Sell | Open Market | 200 | $3K | 11/26/2025 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 11,111 | $0 | 7/10/2025 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 8,013 | — | 5/31/2025 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,924 | $59K | 5/31/2025 | View on chart |
| COLL | ▲ Buy | Grant | 9,791 | $0 | 5/15/2025 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 558 | $15K | 4/11/2025 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 3,752 | — | 4/11/2025 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 2,323 | — | 4/11/2025 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 901 | $24K | 4/11/2025 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 20,000 | $0 | 2/9/2025 | View on chart |
| COLL | ▲ Buy | Grant | 12,726 | $0 | 2/4/2025 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 75,134 | $0 | 1/6/2025 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 12,667 | $0 | 1/5/2025 | View on chart |
| EYPT | ▲ Buy | Open Market | 3,173 | $25K | 8/16/2024 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 11,111 | $0 | 7/10/2024 | View on chart |
| EYPT | ▼ Sell | Gift | 74,681 | $0 | 2/13/2024 | View on chart |
| EYPT | ▼ Sell | Gift | 74,681 | $0 | 2/13/2024 | View on chart |
| EYPT | ▼ Sell | Tax Withholding | 6,981 | $201K | 2/9/2024 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 17,534 | $0 | 2/9/2024 | View on chart |
| EYPT | ▼ Sell | Tax Withholding | 7,962 | $229K | 2/9/2024 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 20,000 | $0 | 2/9/2024 | View on chart |
| EYPT | ▼ Sell | Open Market | 29,956 | $748K | 1/24/2024 | View on chart |
| EYPT | ▼ Sell | Open Market | 5,044 | $126K | 1/23/2024 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 75,133 | $0 | 1/6/2024 | View on chart |
| EYPT | ▼ Sell | Tax Withholding | 23,043 | $470K | 1/6/2024 | View on chart |
| EYPT | ▼ Sell | Open Market | 20,000 | $415K | 12/4/2023 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 17,533 | $0 | 2/9/2023 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 20,000 | $0 | 2/9/2023 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 12,466 | $0 | 2/28/2022 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 13,717 | $0 | 2/21/2022 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 17,533 | $0 | 2/9/2022 | View on chart |
| EYPT | ▼ Sell | Open Market | 10,000 | $201K | 11/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Baird Highlights Growth Potential for Alkermes plc (ALKS)
Baird has highlighted Alkermes plc as a company with promising growth potential, citing its pipeline and recent developments. A Yahoo article compares Alkermes to LQDA, discussing which biotech may be more attractive for investors. The stock is currently trading near its 200‑day moving average and close to a key support level of $48.74, while analysts average a target of $56.56.
Baird Highlights Growth Potential for Alkermes plc (ALKS). Baird has highlighted Alkermes plc as a company with promising growth potential, citing its pipeline and recent developments. A Yahoo article compares Alkermes to LQDA, discussing which biotech may be more attractive for investors. The stock is currently trading near its 200‑day moving average and close to a key support level of $48.74, while analysts average a target of $56.56.